In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer.

The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit in cancer to cover the much-watched area of T cell engagers that can compete with CAR Ts...